The Ratio of RAC1B to RAC1 Expression in Breast Cancer Cell Lines as a Determinant of Epithelial/Mesenchymal Differentiation and Migratory Potential.
RAC1
RAC1B
breast cancer
chemokinesis
diagnostic marker
epithelial subtype
invasion
mesenchymal
migration
phenotype
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 02 2021
08 02 2021
Historique:
received:
17
12
2020
revised:
27
01
2021
accepted:
03
02
2021
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Breast cancer (BC) is a heterogenous disease encompassing tumors with different histomorphological phenotypes and transcriptionally defined subtypes. However, the non-mutational/epigenetic alterations that are associated with or causally involved in phenotype diversity or conversion remain to be elucidated. Data from the pancreatic cancer model have shown that the small GTPase RAC1 and its alternatively spliced isoform, RAC1B, antagonistically control epithelial-mesenchymal transition and cell motility induced by transforming growth factor β. Using a battery of established BC cell lines with either a well-differentiated epithelial or poorly differentiated mesenchymal phenotype, we observed subtype-specific protein expression of RAC1B and RAC1. While epithelial BC lines were RAC1B
Identifiants
pubmed: 33567745
pii: cells10020351
doi: 10.3390/cells10020351
pmc: PMC7915250
pii:
doi:
Substances chimiques
RAC1 protein, human
0
rac1 GTP-Binding Protein
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Cancers (Basel). 2020 Nov 22;12(11):
pubmed: 33266416
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817656
Cells. 2019 Jan 04;8(1):
pubmed: 30621237
Dev Cell. 2018 Jun 18;45(6):681-695.e4
pubmed: 29920274
J Biol Chem. 2003 Dec 12;278(50):50442-8
pubmed: 14506233
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Cancer Sci. 2018 May;109(5):1648-1659
pubmed: 29575318
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Oncotarget. 2017 Aug 16;8(42):73329-73344
pubmed: 29069872
Cancer Res. 1998 May 1;58(9):1972-7
pubmed: 9581841
Cancer Sci. 2008 Feb;99(2):272-9
pubmed: 18271926
J Biomech Eng. 2020 Apr 29;:
pubmed: 32346724
Oncogene. 2000 Jun 15;19(26):3013-20
pubmed: 10871853
RNA. 2014 Apr;20(4):474-82
pubmed: 24550521
Oncotarget. 2014 Jan 15;5(1):277-90
pubmed: 24378395
Nature. 2005 Jul 7;436(7047):123-7
pubmed: 16001073
Cancer Lett. 2018 Apr 10;419:187-202
pubmed: 29331414
Sci Rep. 2017 Dec 11;7(1):17313
pubmed: 29229918
Cancer Res. 2007 Mar 1;67(5):2124-30
pubmed: 17332342
Cells. 2019 Dec 04;8(12):
pubmed: 31817229
Int J Mol Sci. 2017 Jul 20;18(7):
pubmed: 28726720
Hum Mol Genet. 2009 Oct 1;18(19):3696-707
pubmed: 19602482
PLoS One. 2015 Jan 21;10(1):e0117310
pubmed: 25607950
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244556
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Cancers (Basel). 2010 May 28;2(2):1040-65
pubmed: 24281106
Anticancer Agents Med Chem. 2017;17(4):491-499
pubmed: 27456662